Methods of treating or preventing erectile dysfunction

Details Methods of treating or preventing erectile dysfunction Methods of treating or preventing erectile dysfunction

2006-07-04

2006-07-04

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S646000, C514S288000

Reexamination Certificate

active

07071234

ABSTRACT:
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3antagonists.

REFERENCES:
patent: 3155669 (1964-11-01), Janssen et al.
patent: 3155670 (1964-11-01), Janssen et al.
patent: 3471515 (1969-10-01), Troxler et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960891 (1976-06-01), Malen et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4522828 (1985-06-01), Jeffrey et al.
patent: 4552828 (1985-11-01), Toya et al.
patent: 4746680 (1988-05-01), Jeffrey et al.
patent: 4806570 (1989-02-01), Jeffrey et al.
patent: 4814352 (1989-03-01), Jeffery et al.
patent: 4816488 (1989-03-01), Rees
patent: 4871774 (1989-10-01), Rees
patent: 4929629 (1990-05-01), Jeffrey
patent: 4939175 (1990-07-01), Ukai et al.
patent: 4988814 (1991-01-01), Abou-Gharbia et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5068440 (1991-11-01), Jeffrey et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5436272 (1995-07-01), Scheinbaum
patent: 5459164 (1995-10-01), Vargas
patent: 5552429 (1996-09-01), Wong et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674553 (1997-10-01), Shinoda et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5780051 (1998-07-01), Eswara et al.
patent: 5795880 (1998-08-01), Svec et al.
patent: 6127363 (2000-10-01), Doherty et al.
patent: 6339106 (2002-01-01), Jerussi et al.
patent: 32 12 682 (1982-10-01), None
patent: 0 035 597 (1981-09-01), None
patent: 0 781 561 (1997-07-01), None
patent: 2098602 (1982-11-01), None
patent: WO 88/06444 (1988-09-01), None
patent: WO 90/06110 (1990-06-01), None
patent: WO 94/00047 (1994-01-01), None
patent: WO 94/00114 (1994-01-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 95/20949 (1995-08-01), None
patent: WO 95/21615 (1995-08-01), None
patent: WO 97/03675 (1997-02-01), None
patent: WO 97/20810 (1997-06-01), None
patent: WO 98/06722 (1998-02-01), None
patent: WO 98/11884 (1998-03-01), None
patent: WO 98/13033 (1998-04-01), None
patent: WO 98/13034 (1998-04-01), None
patent: WO 99/33450 (1999-07-01), None
Baldessarini et al.,Life Sciences39: 1765-1777, (1986).
Buckett et al.,Prog. Neuro-psychopharm.&Biol. Psychiat., 12:575-584 (1988).
Buckett et al., “Sibutramine Hydrochloride,”Drugs of the Future13(8): 736-738 (1988).
Buckett et al.,New Concepts in Depression2: 167-172 (1988).
Butler, D.,J. Org. Chem.,36:1308 (1971).
Canonne, P., et al.,Tetrahedron Lett.,21:155-58 (1980).
Carstensen, J.,Drug Stability: Principles&Practice, 2d. Ed., pp. 379-380, Marcel Dekker, NY, NY, (1995).
Castello, R.A., and Mattocks, A.M.,Pharm. Sci. 51(2):106-108 (1962).
Cheetham, S.C., et al.,Neuropharmacology(1993), 32(8), 737-43, XP000905163 (abs.).
Cliffe et al.,Med. Chem.,36:1509-1510 (1993).
Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed., American Psychiatric Association, (1997).
Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed., American Psychiatric Association (1981).
Dreshfield et al.,Neurochem. Res.,vol. 21 (5):557-562 (1996).
Eliel, E.L.,Stereochemistry of Carbon Compounds(McGraw-Hill, NY, 1962).
Evans et al.,J.A.M.A.262: 2551-2556 (1989).
Fuentes, J.et al.,Chemical Abstracts, 85: 7, p. 31, No. 40768t (1976).
Goodman&Gilman, The Pharmacological Basis of Therapeutics, 362-373, 404 (9thed. McGraw-Hill,(1996).
Gray, A.M., et al.,BR. J. Pharmacol.,vol. 124, No. 4, (1998,)pp. 669-674, XP000909217 (abs.).
Handbook of Pharmaceutical Excipients, 2nded., Wade and Willer eds., pp. 257-259 (1994).
Heal, D.J., et al.,BR. J. Pharmacol. (1998), 125(2), 301-308, XP000905054 (abs.).
Hillyer et al.,J. Med. Chem.,33:1541-44 (1990).
Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
J. Med. Chem.,vol. 36, No. 17 2540 (1993).
Jacques et al., “Enantiomers, Racemates and Resolutions,” (Wiley-Interscience, NY, 1981).
Jamali et al.,Journal of Pharmaceutical Sciences, 78: 9: 695-715 (1989).
Jeffery, J. E., et al.,J. Chem. Soc. Perkin. Trans I, 2583-2589 (1996).
King et al.,Clinical Pharmac. 26: 607-611 (1989).
Kula et al.,Life Sciences34(26): 2567-2575, (1984).
Luscombe, G.P., et al.,Neuropharmacology, 28(2): pp. 129-134 (1989), XP000613753 ISSSN: 0028-3908 (abs.).
Middlmiss et al.,Nuerosci. and Biobehv. Rev.,16:75-82 (1992).
Moreau et al.,Brain Res. Bull., 29:901-04 (1992).
Nakada, N., et al.,Tetrahedron Lett.,38:857-860 (1997).
Physician's Desk Reference® 2520 (52nded., 1998).
Physician's Desk Reference® 2958 (52nded., 1998).
Physician's Desk Reference® 473-475 (53rded., 1999).
Physician's Desk Reference® 475-476 (53rded., 1999).
Physician's Desk Reference® 764-766 (53rded., 1999).
Physician's Desk Reference® 823-825 (53rded., 1999).
Physician's Desk Reference® 978-979 (53rded., 1999).
Physician's Desk Reference® 1054-1056 (53rded., 1999).
Physician's Desk Reference® 1332-1334 (53rded., 1999).
Physician's Desk Reference® 1369-1370 (53rded., 1999).
Physician's Desk Reference® 1432-1436 (53rded., 1999).
Physician's Desk Reference® 1494-1498 (53rded., 1999).
Physician's Desk Reference® 1641-1645 (53rded., 1999).
Physician's Desk Reference® 2004-2009 (53rded., 1999).
Physician's Desk Reference® 2075-2078 (53rded., 1999).
Physician's Desk Reference® 2190-2192 (53rded., 1999).
Physician's Desk Reference® 2367-2368 (53rded., 1999).
Physician's Desk Reference® 2396-2399 (53rded., 1999).

Affiliated with

Also associated with

Rating

Methods of treating or preventing erectile dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating or preventing erectile dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating or preventing erectile dysfunction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3608785